NEW YORK (GenomeWeb) – Fulgent Genetics this week said in a regulatory document that it has formed a joint venture in China to offer genetic testing services in that country.

In a document filed with the US Securities Exchange Commission, Fulgent said it has formed a joint venture with Chinese firms Xilong Scientific and Fuzhou Jinqiang Investment Partnership (FJIP) to establish Fujian Fujun Gene Biotech. Under the agreement Fulgent will provide to the JV genetic sequencing and other equipment costing no more than about RMB60 million ($8.7 million) over a three-year period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.